Clinical Trials Logo

Acoustic Neuroma clinical trials

View clinical trials related to Acoustic Neuroma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06322342 Recruiting - Multiple Sclerosis Clinical Trials

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.

NCT ID: NCT04004377 Recruiting - Acoustic Neuroma Clinical Trials

Acoustic Neuroma: Assessing the Quality of Life by the Scale PANQOL of Patients Operated or Supervised

PANQOL
Start date: December 5, 2018
Phase:
Study type: Observational

This study has investigated the quality of life of patients with vestibular schwannoma using this specific scale prospectively, whether treated surgically or monitored.

NCT ID: NCT03393689 Recruiting - Acoustic Neuroma Clinical Trials

RGD PET/MRI in Sporadic Vestibular Schwannoma

Start date: January 2, 2018
Phase: Phase 2
Study type: Interventional

The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of angiogenesis PET/MR with the radioligand 68Ga-NODAGA- E[c(RGDyK)]2 in patients with sporadic Vestibuarl Schwannomas.

NCT ID: NCT03079999 Recruiting - Clinical trials for Vestibular Schwannoma

Study of Aspirin in Patients With Vestibular Schwannoma

Start date: June 11, 2018
Phase: Phase 2
Study type: Interventional

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.